ProMIS Expects Cash Resources to Fund Operations Through 2027
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Existing cash resources of $63.8M at quarter end are expected to fund planned operations through 2027, including the completion of the PRECISE-AD trial. "2026 has the potential to be a significant year for patients with Alzheimer's disease and their caregivers," said CEO Neil Warma. "We believe ProMIS is well-positioned with PMN310 as a potentially differentiated treatment for patients with early AD. We are coming off a productive quarter, having closed a transformational financing of up to $175M, including potential proceeds from warrant exercises, and have executed well on our Phase 1b clinical trial. Near-term data catalysts, including the blinded 6-month interim analysis, are anticipated in early Q3 2026, and could provide important insight into the potential of our lead drug candidate, PMN310... ProMIS expects to complete 12-month dosing for all patients by year-end and to report unblinded top-line results in early 2027, providing a comprehensive view of PMN310's safety, biomarker, and clinical outcomes by treatment group, and an important clinical test of PMN310's selective targeting approach."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMN
Wall Street analysts forecast PMN stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.870
Low
18.00
Averages
29.33
High
35.00
Current: 10.870
Low
18.00
Averages
29.33
High
35.00
About PMN
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ProMIS Neurosciences to Participate in Multiple Upcoming Conferences
- Conference Participation: ProMIS Neurosciences will participate in several conferences in June 2026, including the Jefferies Global Healthcare Conference in New York, where they will present on June 4, enhancing investor confidence in their research capabilities in neurodegenerative disease treatments.
- Product Presentation: CEO Neil Warma will discuss the EpiSelect™ platform and the Alzheimer's candidate PMN310, which selectively targets toxic amyloid-beta oligomers, potentially reducing off-target effects associated with traditional therapies, thereby improving treatment outcomes.
- Clinical Trial Data: ProMIS expects to report blinded interim data from its PRECISE-AD Phase 1b trial in early Q3 2026, with 12-month topline data anticipated in early 2027, providing crucial insights into their Alzheimer's treatment progress for investors.
- Market Outlook: With increasing demand for neurodegenerative disease treatments, ProMIS's innovative approach and upcoming data releases are likely to attract more investor attention, further solidifying its market position in the biotechnology sector.
See More
ProMIS Neurosciences Reports Q1 2026 Financial Results
- Financial Performance: ProMIS Neurosciences reported a GAAP EPS of -$1.26 for Q1 2026, indicating challenges in profitability, although cash and cash equivalents stood at $63.8 million, reflecting $75.5 million in gross up-front proceeds from February financing.
- Cash Flow Outlook: As of March 31, 2026, the company's cash resources are expected to fund operations through 2027, including the completion of the PRECISE-AD trial, demonstrating a proactive approach to financial management.
- Net Loss Comparison: The net loss for Q1 2026 was $8.2 million, an increase from $7.3 million in the same period of 2025, highlighting ongoing challenges in cost control and revenue generation.
- Financing Impact: Despite the quarterly losses, the cash flow secured through successful financing provides a buffer for future R&D and operations, indicating the company's appeal in capital markets and potential growth opportunities.
See More
ProMIS Secures $175 Million Financing to Support Alzheimer's Clinical Trial
- Successful Financing: ProMIS Neurosciences has closed PIPE financing of up to $175 million, which will fund operations through 2027, particularly for the Alzheimer's Phase 1b clinical trial, reflecting strong market confidence and financial backing for the company.
- Clinical Trial Progress: The PRECISE-AD Phase 1b trial was fully enrolled in December 2025 with 144 participants receiving treatment over 12 months, with a blinded interim analysis expected in Q3 2026, potentially providing early insights into the efficacy of PMN310, which is clinically significant.
- Safety Concerns: Current Alzheimer's therapies carry serious safety risks, and ProMIS's PMN310 aims to selectively target toxic amyloid-beta oligomers while avoiding plaque binding, potentially reducing ARIA-related risks and enhancing patient treatment experiences.
- Future Outlook: The company anticipates releasing 12-month topline data in early 2027, which will comprehensively assess PMN310's safety and biomarker outcomes, further validating its potential in Alzheimer's treatment and possibly transforming the existing treatment landscape.
See More
Promis Neurosciences Plans to Raise $200M
- Funding Initiative: Promis Neurosciences has announced a shelf prospectus to raise up to $200 million through various securities offerings, including common shares, preferred shares, subscription receipts, debt securities, warrants, and units, aimed at enhancing the company's financial flexibility and market competitiveness.
- Diverse Securities Offering: The securities may be sold individually or in combination, demonstrating the company's flexibility in its financing strategy, allowing it to adjust the offering structure based on market demand and investor interest, thereby maximizing the effectiveness of the fundraising.
- Market Reaction Outlook: The market holds a cautiously optimistic view on Promis Neurosciences' funding plan, which is expected to provide essential financial support for the company's future R&D and operations, aiding its innovation and development in the neuroscience field.
- Strategic Implications: This funding initiative not only strengthens Promis Neurosciences' capital base but also secures financial backing for future clinical trials and product development, further driving the company's growth and market share expansion in the biopharmaceutical industry.
See More
ProMIS Neurosciences Reports 2025 Financial Results and Pipeline Updates
- Financial Performance: ProMIS Neurosciences reported a net loss of $39.72 million for FY2025, translating to a loss of $22.61 per share, a stark contrast to last year's net income of $2.78 million and earnings of $2.63 per share, indicating significant challenges in R&D investment that may impact future funding capabilities.
- Cash Position: As of December 31, 2025, the company had $6.1 million in cash, and following a private placement in February 2026 that raised $75.5 million, these resources are expected to fund operations through 2027, ensuring the continuation of critical clinical trials.
- Clinical Trial Progress: Following encouraging results from the Phase 1a trial of PMN310 in healthy volunteers, ProMIS initiated the PRECISE-AD Phase 1b clinical trial in Alzheimer's patients, successfully enrolling 144 participants, exceeding the target of 128, reflecting strong market interest in the therapy.
- Market Potential: According to Grand View Research, the global Alzheimer's therapeutics market was estimated at $4.05 billion in 2022 and is projected to reach $15.19 billion by 2030, growing at a CAGR of 19.99%, presenting substantial commercial opportunities for ProMIS's product development.
See More
PROMIS NEUROSCIENCES INC MAY ISSUE SECURITIES WORTH UP TO $200 MILLION, ACCORDING TO SEC FILING
Investment Announcement: PROMIS Neurosciences is offering securities worth up to $200 million.
Purpose of Funding: The funds are intended to support the company's ongoing research and development efforts.
See More
ProMIS Neurosciences to Participate in Multiple Upcoming Conferences
- Conference Participation: ProMIS Neurosciences will participate in several conferences in June 2026, including the Jefferies Global Healthcare Conference in New York, where they will present on June 4, enhancing investor confidence in their research capabilities in neurodegenerative disease treatments.
- Product Presentation: CEO Neil Warma will discuss the EpiSelect™ platform and the Alzheimer's candidate PMN310, which selectively targets toxic amyloid-beta oligomers, potentially reducing off-target effects associated with traditional therapies, thereby improving treatment outcomes.
- Clinical Trial Data: ProMIS expects to report blinded interim data from its PRECISE-AD Phase 1b trial in early Q3 2026, with 12-month topline data anticipated in early 2027, providing crucial insights into their Alzheimer's treatment progress for investors.
- Market Outlook: With increasing demand for neurodegenerative disease treatments, ProMIS's innovative approach and upcoming data releases are likely to attract more investor attention, further solidifying its market position in the biotechnology sector.
See More
ProMIS Neurosciences Reports Q1 2026 Financial Results
- Financial Performance: ProMIS Neurosciences reported a GAAP EPS of -$1.26 for Q1 2026, indicating challenges in profitability, although cash and cash equivalents stood at $63.8 million, reflecting $75.5 million in gross up-front proceeds from February financing.
- Cash Flow Outlook: As of March 31, 2026, the company's cash resources are expected to fund operations through 2027, including the completion of the PRECISE-AD trial, demonstrating a proactive approach to financial management.
- Net Loss Comparison: The net loss for Q1 2026 was $8.2 million, an increase from $7.3 million in the same period of 2025, highlighting ongoing challenges in cost control and revenue generation.
- Financing Impact: Despite the quarterly losses, the cash flow secured through successful financing provides a buffer for future R&D and operations, indicating the company's appeal in capital markets and potential growth opportunities.
See More
ProMIS Secures $175 Million Financing to Support Alzheimer's Clinical Trial
- Successful Financing: ProMIS Neurosciences has closed PIPE financing of up to $175 million, which will fund operations through 2027, particularly for the Alzheimer's Phase 1b clinical trial, reflecting strong market confidence and financial backing for the company.
- Clinical Trial Progress: The PRECISE-AD Phase 1b trial was fully enrolled in December 2025 with 144 participants receiving treatment over 12 months, with a blinded interim analysis expected in Q3 2026, potentially providing early insights into the efficacy of PMN310, which is clinically significant.
- Safety Concerns: Current Alzheimer's therapies carry serious safety risks, and ProMIS's PMN310 aims to selectively target toxic amyloid-beta oligomers while avoiding plaque binding, potentially reducing ARIA-related risks and enhancing patient treatment experiences.
- Future Outlook: The company anticipates releasing 12-month topline data in early 2027, which will comprehensively assess PMN310's safety and biomarker outcomes, further validating its potential in Alzheimer's treatment and possibly transforming the existing treatment landscape.
See More
Promis Neurosciences Plans to Raise $200M
- Funding Initiative: Promis Neurosciences has announced a shelf prospectus to raise up to $200 million through various securities offerings, including common shares, preferred shares, subscription receipts, debt securities, warrants, and units, aimed at enhancing the company's financial flexibility and market competitiveness.
- Diverse Securities Offering: The securities may be sold individually or in combination, demonstrating the company's flexibility in its financing strategy, allowing it to adjust the offering structure based on market demand and investor interest, thereby maximizing the effectiveness of the fundraising.
- Market Reaction Outlook: The market holds a cautiously optimistic view on Promis Neurosciences' funding plan, which is expected to provide essential financial support for the company's future R&D and operations, aiding its innovation and development in the neuroscience field.
- Strategic Implications: This funding initiative not only strengthens Promis Neurosciences' capital base but also secures financial backing for future clinical trials and product development, further driving the company's growth and market share expansion in the biopharmaceutical industry.
See More
ProMIS Neurosciences Reports 2025 Financial Results and Pipeline Updates
- Financial Performance: ProMIS Neurosciences reported a net loss of $39.72 million for FY2025, translating to a loss of $22.61 per share, a stark contrast to last year's net income of $2.78 million and earnings of $2.63 per share, indicating significant challenges in R&D investment that may impact future funding capabilities.
- Cash Position: As of December 31, 2025, the company had $6.1 million in cash, and following a private placement in February 2026 that raised $75.5 million, these resources are expected to fund operations through 2027, ensuring the continuation of critical clinical trials.
- Clinical Trial Progress: Following encouraging results from the Phase 1a trial of PMN310 in healthy volunteers, ProMIS initiated the PRECISE-AD Phase 1b clinical trial in Alzheimer's patients, successfully enrolling 144 participants, exceeding the target of 128, reflecting strong market interest in the therapy.
- Market Potential: According to Grand View Research, the global Alzheimer's therapeutics market was estimated at $4.05 billion in 2022 and is projected to reach $15.19 billion by 2030, growing at a CAGR of 19.99%, presenting substantial commercial opportunities for ProMIS's product development.
See More
PROMIS NEUROSCIENCES INC MAY ISSUE SECURITIES WORTH UP TO $200 MILLION, ACCORDING TO SEC FILING
Investment Announcement: PROMIS Neurosciences is offering securities worth up to $200 million.
Purpose of Funding: The funds are intended to support the company's ongoing research and development efforts.
See More
